Ernst R. Berndt | Academic Influence

Why Is Ernst R. Berndt Influential?

Ernst R. Berndt's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Estimation and Inference in Nonlinear Structural Models (1974) (2296)
Technology, Prices, and the Derived Demand for Energy (1975) (1435)
The economic burden of anxiety disorders in the 1990s. (1999) (1275)
The Practice of Econometrics: Classic and Contemporary. (1992) (1261)
The economic burden of depression in 1990. (1993) (1029)
The translog function and the substitution of equipment, structures, and labor in U.S. manufacturing 1929-68 (1973) (754)
Estimation and Hypothesis Testing in Singular Equation Systems with Autoregressive Disturbances (1975) (548)
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007) (494)
Engineering and Econometric Interpretations of Energy-Capital Complementarity: Reply and Further Results (1979) (454)
Parametric Productivity Measurement and Choice Among Flexible Functional Forms (1979) (435)
Unemployment, job retention, and productivity loss among employees with depression. (2004) (413)
Pricing in the Market for Anticancer Drugs (2014) (384)
High-tech capital formation and economic performance in U.S. manufacturing industries : an exploratory analysis (1992) (364)
Promotion of prescription drugs to consumers. (2002) (355)
Measuring the Contribution of Public Infrastructure Capital in Sweden (1991) (340)
The impact of treatment-resistant depression on health care utilization and costs. (2002) (338)
Productivity measurement with adjustments for variations in capacity utilization and other forms of temporary equilibrium (1986) (327)
The Internal Structure of Functional Relationships: Separability, Substitution, and Aggregation (1973) (326)
Trends in the globalization of clinical trials (2008) (315)
The Practice of Econometrics (1991) (286)
Reconciling Alternative Estimates of the Elasticity of Substitution (1976) (284)
CONFLICT AMONG CRITERIA FOR TESTING HYPOTHESES IN THE MULTIVARIATE LINEAR REGRESSION MODEL (1977) (260)
Relationship of Employee-Reported Work Limitations to Work Productivity (2003) (259)
Testing for the Existence of a Consistent Aggregate Index of Labor Inputs (1974) (257)
Econometric Estimates of Prices Indexes for Personal Computers in the 1990s (1993) (250)
Lost human capital from early-onset chronic depression. (2000) (226)
Information, marketing, and pricing in the U.S. antiulcer drug market. (1995) (218)
Modeling and measuring natural resource substitution (1981) (217)
High-Tech Capital Formation and Labor Composition in U.S. Manufacturing Industries: An Exploratory Analysis (1992) (212)
Workplace performance effects from chronic depression and its treatment. (1998) (208)
Capacity Utilization Measures: Underlying Economic Theory and an Alternative Approach (1981) (195)
The Clinical and Occupational Correlates of Work Productivity Loss Among Employed Patients With Depression (2004) (193)
Depression: a neglected major illness. (1993) (180)
Price Indexes for Microcomputers: an Exploratory Study (1990) (179)
Pharmaceuticals in U.S. health care: determinants of quantity and price. (2002) (174)
Price and Quality of Desktop and Mobile Personal Computers: A Quarter-Century Historical Overview (2001) (169)
Prescription drug spending trends in the United States: looking beyond the turning point. (2008) (159)
The practice of econometrics : classic and contemporary (1993) (157)
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs (2000) (157)
Loss of work productivity due to illness and medical treatment. (1999) (155)
Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression (2004) (155)
Flexible Functional Forms and Expenditure Distributions: An Application to Canadian Consumer Demand Functions (1977) (153)
Aggregate Energy, Efficiency, and Productivity Measurement (1978) (148)
The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected Outcome Variations, and Price Indexes (2000) (140)
The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry (1994) (139)
Measuring and assessing capacity utilization in the manufacturing sectors of nine oecd countries (1986) (136)
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation (2010) (129)
The value of antihypertensive drugs: a perspective on medical innovation. (2007) (126)
Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants (2004) (125)
Medical Care Prices and Output (2000) (121)
The cost consequences of treatment-resistant depression. (2004) (116)
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. (2007) (115)
Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs (1996) (107)
The U.S. pharmaceutical industry: why major growth in times of cost containment? (2001) (105)
Demand Effects of Recent Changes in Prescription Drug Promotion (2003) (104)
Authorized generic drugs, price competition, and consumers' welfare. (2007) (101)
Quantifying factors for the success of stratified medicine (2011) (101)
Energy use, technical progress and productivity growth: A survey of economic issues (1990) (99)
Auditing the Producer Price Index: Micro Evidence from Prescription Pharmaceutical Preparations (1992) (96)
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates (2005) (92)
Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales* (2002) (89)
Rail Costs and Capital Adjustments in a Quasi-Regulated Environment (1991) (88)
Promotion of Prescription Drugs to Consumers and Providers, 2001–2010 (2013) (88)
Fifty Years of Economic Measurement (1992) (86)
Dynamic Econometric Modeling (1988) (77)
The Emerging Position of the Internet as an Advertising Medium (2001) (74)
Pricing and Reimbursement in U.S. Pharmaceutical Markets (2010) (74)
Medical Care Output and Productivity (2001) (73)
Cost effects of mergers and deregulation in the U.S. Rail industry (1993) (72)
The economic burden of anemia in cancer patients receiving chemotherapy. (2005) (72)
Decline in economic returns from new drugs raises questions about sustaining innovations. (2015) (71)
Measuring the Energy Efficiency and Productivity Impacts of Embodied Technical Change (1993) (68)
Fifty Years of Economic Measurement: The Jubilee of the Conference on Research in Income and Wealth (1992) (66)
The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches (2003) (65)
To inform or persuade? Direct-to-consumer advertising of prescription drugs. (2005) (65)
Tax Credits for Employment Rather Than Investment (1977) (62)
Productivity Measurement Using Capital Asset Valuation to Adjust for Variations in Utilization (1982) (59)
Scale and Scope Effects on Advertising Agency Costs (1990) (58)
Price Indexes for the Treatment of Depression (1998) (58)
Generic Entry, Reformulations and Promotion of SSRIs in the US (2012) (58)
Faster, smaller, cheaper: an hedonic price analysis of PDAs (2004) (57)
Health care use and at-work productivity among employees with mental disorders. (2000) (56)
Demand for Natural Gas: Residential and Commercial Markets in Ontario and British Columbia (1977) (54)
Dynamic models of the industrial demand for energy (1977) (52)
An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. (2002) (52)
Vaccine advance-purchase agreements for low-income countries: practical issues. (2005) (49)
Economic Consequences of Illness in the Workplace (1995) (49)
Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. (1999) (47)
The Long Shadow of Patent Expiration (2003) (47)
Measuring the Contribution of Capital in Sweden (1992) (43)
Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group. (1996) (43)
Objective and self‐report work performance measures: a comparative analysis (2006) (42)
The Impact of Incremental Innovation in Biopharmaceuticals (2006) (41)
Energy price changes and the induced revaluation of durable capital in U.S. manufacturing (1983) (41)
Introduction to "Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches" (2007) (41)
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? (2010) (40)
A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets (2011) (39)
Alternate Insurance Arrangements and the Treatment of Depression: What are the Facts? (1996) (38)
Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts (2008) (38)
Advance market commitment for pneumococcal vaccines: putting theory into practice. (2011) (37)
Economic perspectives on the advance market commitment for pneumococcal vaccines. (2011) (37)
Measuring Prices and Quantities of Treatment for Depression (1998) (37)
Energy demand in the transportation sector of Mexico (1985) (37)
Treatment Price Indexes for Acute Phase Major Depression (2001) (36)
Economic Capacity Utilization and Productivity Measurement for Multi-Product Firms with Multiple Quasi-Fixed Inputs (1989) (36)
Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases (2010) (35)
Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. (2004) (34)
Price Indexes for Clinical Trial Research: A Feasibility Study (2013) (34)
Has The Era Of Slow Growth For Prescription Drug Spending Ended? (2016) (34)
The net value of health care for patients with type 2 diabetes, 1997 to 2005. (2009) (33)
The Landscape of Us Generic Prescription Drug Markets, 2004-2016 (2017) (33)
From technocracy to net energy analysis : engineers, economists and recurring energy theories of value (1982) (32)
Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms (1994) (31)
How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. (2013) (31)
QUALITY-CONSTANT "PRICES" FOR THE ONGOING TREATMENT OF SCHIZOPHRENIA: AN EXPLORATORY STUDY* (2004) (30)
Panel data analysis of U.S. coal productivity (2005) (30)
The Diversity of Concentrated Prescribing Behavior: an Application to Antipsychotics (2011) (30)
The hidden cost of low prices: limited access to new drugs in India. (2014) (30)
Changes in physician antipsychotic prescribing preferences, 2002-2007. (2014) (29)
HIGH-TECH CAPITAL FORMATION AND LABOR COMPOSITION (29)
The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity (2013) (29)
Governance Structure, Managerial Characteristics, and Firm Performance in the Deregulated Rail Industry (1992) (29)
Income redistribution and employment effects of rising energy prices (1979) (29)
Rates of Return and Capital Aggregation, Using Alternative Rental Prices (2015) (28)
Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy (2012) (27)
Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007 (2014) (26)
The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. (2015) (26)
Sources of Productivity Growth in the American Coal Industry 1972-95 (1998) (26)
Dynamic Competition in Pharmaceuticals: Cross-National Evidence from New Drug Diffusion (2007) (26)
Early Retirement and Public Disability Insurance Applications: Exploring the Impact of Depression (2006) (25)
International comparisons of pharmaceutical prices: what do we know, and what does it mean? (2000) (25)
Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs (1997) (25)
Information Technology And The Productivity Paradox: Getting The Questions Right (1995) (25)
Advance Market Commitment for Pneumococcal Vaccines: Putting Theory into practice/Engagement Prealable Relatif Au Marche Pour Les Vaccins Contre le Pneumocoque: Mettre la Theorie En pratique/Compromiso De Mercado Avanzado Para Vacunas Neumococicas: Poniendo En Practica la Teoria (2011) (24)
Short run labor productivity in a dynamic model (2015) (24)
Assessing the Safety and Efficacy of the Fda: The Case of the Prescription Drug User Fee Acts (2005) (23)
Engineering and econometric approaches to industrial energy conservation and capital formation : a reconciliation (1977) (23)
ENERGY PRICE SHOCKS AND PRODUCTIVITY GROWTH IN US AND UK MANUFACTURING (1986) (23)
Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care (1999) (23)
Prescription Drug Prices for the Elderly (1998) (22)
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (2004) (21)
On Testing Theories of Financial Intermediary Portfolio Selection (1980) (20)
Price Indexes for Acute Phase Treatment of Depression (1998) (20)
The Boskin Commission Report After a Decade: After-life or Requiem? (2006) (20)
Holding Company Cost Economies in the Global Advertising and Marketing Services Business (2004) (20)
Mergers, Deregulation and Cost Savings in the U.S. Rail Industry (1991) (19)
The demand for electricity: comment and further results (1978) (18)
Depression treatment: a lifelong commitment? (2002) (18)
Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development (2013) (18)
Performance Decrements Resulting From Illness in the Workplace: The Effect of Headaches (2005) (18)
Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. (2000) (18)
Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009. (2011) (17)
Anomalies in Estimates of Cross-Price Elasticities for Marketing Mix Models: Theory and Empirical Test (2006) (17)
Pharmaceutical Innovation: The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned? (2007) (17)
The impact of anaemia and its treatment on employee disability and medical costs (2012) (16)
Economic challenges and possible policy actions to advance stratified medicine. (2012) (16)
NBER WORKING PAPER SERIES PRICE INDEXES FOR MICROSOFT’S PERSONAL COMPUTER SOFTWARE PRODUCTS (2003) (16)
The Segmentation of Therapeutic Populations in Oncology (2012) (16)
The generic drug user fee amendments: an economic perspective (2017) (16)
Calculating the workplace cost of chronic disease. (1995) (15)
The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. (2015) (15)
Economic Factors Underlying the Unbundling of Advertising Agency Services (2008) (15)
Interdependent Pricing and Markup Behavior: an Empirical Analysis of GM, Ford and Chrysler (1990) (14)
Real Output in Mental Health Care during the 1990s (2005) (14)
Patterns of Antipsychotic Prescribing by Physicians to Young Children. (2016) (14)
Energy prices and productivity trends in the Canadian manufacturing sector, 1957-76 : some exploratory results (1981) (13)
Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. (2013) (12)
EFFICIENCY, AND PRODUCTIVITY MEASUREMENT (1978) (12)
On the Accuracy of Producer Price Indexes for Pharmaceutical Preparations: An Audit Based on Detailed Firm-Specific Data (1990) (12)
The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke and Myocardial Infarction in the United States (2006) (12)
How energy, and its cost, enter the `productivity equation¿ (1978) (12)
Creating Price Indexes for Measuring Productivity in Mental Health Care (2001) (12)
When antihistamines go to work. (1999) (11)
Diffusion of New Drugs in the Post-TRIPS Era (2011) (11)
The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs: The Case of Bevacizumab for Breast Cancer (2013) (10)
Energy-Output Coefficients: Complex Realities Behind Simple Ratios (1983) (10)
The Unbundling of Advertising Agency Services: An Economic Analysis (2012) (10)
THE GLOBALIZATION OF CLINICAL TRIALS FOR NEW MEDICINES INTO EMERGING ECONOMIES: WHERE ARE THEY GOING AND WHY? (2007) (10)
Energy modeling and simulation (1985) (10)
Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users. (2021) (10)
Market watch: Defining and quantifying the use of personalized medicines (2013) (10)
Investigating investment in biopharmaceutical R&D (2016) (10)
An empirical investigation of the box-cox model and a nonlinear least squares alternative (1993) (9)
Measuring and Modeling Health Care Costs (2018) (9)
Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety. (2002) (9)
Economic Incentives and Contracts: The Use of Psychotropic Medications (2008) (9)
Unique issues raised by drug benefit design. (2004) (9)
Restructuring in the U.S. Advertising Media Industry (1999) (9)
Characterization of annual disease progression of multiple sclerosis patients: A population-based study (2018) (9)
Radiologist productivity: what, why, and how. (2009) (8)
Modeling Energy Demand: The Choice Between Input and Output Energy Measures (1986) (8)
Hard-to-Measure Goods and Services (2007) (8)
Direct-to-Consumer Advertising in Health Care: An Overview of Economic Issues by (2006) (8)
Scale and Scope Economies in the Global Advertising and Marketing Services Business (2003) (8)
Assessing the Productivity of Information Technology Equipment in U.S. Manufacturing Industries (1991) (8)
Residential Electricity Demand in Mexico: A Model Distinguishing Access From Consumption (2018) (8)
Technological change, tax policy, and the derived demand for energy (1975) (8)
Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures. (2016) (7)
Dynamic Econometric Modeling: Investment and sales: some empirical evidence (1988) (7)
Changes in the costs of treating mental health disorders (2012) (7)
Quality adjustment in empirical demand analysis (1983) (7)
Antipsychotic Prescribing: Do Conflict of Interest Policies Make a Difference? (2015) (7)
The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines (2019) (7)
Impacts of Patent Expiry on Daily Cost of Pharmaceutical Treatments in Eight OECD Countries, 2004–2010 (2016) (6)
Four Facts Concerning Competition in US Generic Prescription Drug Markets (2019) (6)
Early Retirement and DI/SSI Applications: Exploring the Impact of Depression (2009) (6)
Measuring the costs and benefits of pharmaceutical expenditures (2002) (6)
Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA (2007) (6)
Research on price index measurement : Agendas for the next twenty years (2003) (6)
Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? (2015) (6)
The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory (2017) (5)
Energy, Capital, and Productivity (1979) (5)
System Average Rates and Management Efficiency: A Statistical Benchmark Study of U.S. Investor-Owned Electric Utilities (1996) (5)
Intermedia Substitutability in the U.S. National Advertising Market (1997) (5)
Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010 (2012) (5)
The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration (2019) (5)
Economic Dimensions of Personalized and Precision Medicine (2019) (5)
DEREGULATION , MERGERS , AND COST SAVINGS IN CLASS (5)
Introduction to "Economic Dimensions of Personalized and Precision Medicine" (2018) (4)
A primer on the economics of re-importation of prescription drugs (2007) (4)
The Effect of Fda Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts (2011) (4)
The Translog Production Function and Factor Substitution in U.S. Manufacturing 1929-1968, (1971) (4)
An Evaluation of the CPI Indexes for Prescription Drugs (2018) (4)
CONSISTENT PROJECTIONS OF ENERGY DEMAND AND AGGREGATE ECONOMIC GROWTH: A REVIEW OF ISSUES AND EMPIRICAL STUDIES (1977) (4)
Advanced Markets for a Malaria Vaccine : Estimating Costs and Effectiveness 1 (2005) (4)
An Econometric Model of Alberta Electricity Demand (1980) (4)
Estimation of Logging Costs and Timber Supply Curves from Forest Inventory Data (1979) (4)
Impacts of Patent Expiry of Pharmaceutical Treatments in Eight OECD Countries, 2004-2010 (2016) (4)
Energy Price Shocks and Productivity Growth in the Japanese and U.S. Manufacturing Industries (1991) (4)
Electric Utility Rates and the Evaluation of Management Performance (1995) (3)
Introduction to "Medical Care Output and Productivity" (2001) (3)
Interpreting Changes in Mental Health Expenditures: Minding Our PS and Qs (2000) (3)
A review of the Energy Productivity Center's Least-Cost Energy Strategy study (1981) (3)
The December Effect in FDA Drug Approvals: Assessing the Submissions Echo Hypothesis (2007) (3)
The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications (2019) (3)
Utility Bond Rates and Tax Normalization (1979) (3)
Price Indexes for Microsoft (2007) (3)
Introduction to "Fifty Years of Economic Measurement: The Jubilee of the Conference on Research in Income and Wealth" (1991) (3)
Supreme Court Amicus Brief Regarding Wyeth V. Diana Levine (2008) (2)
The Globalization of Clinical Trials for New Medicines: Where are the Trials Going and Why? (2007) (2)
Advance Market Commitments for Vaccines Working Paper and Spread Sheet (2006) (2)
Electrification, Energy Quality, and Productivity Growth in U.S. Manufacturing (2011) (2)
MEDICARE PART D, PRESCRIPTION DRUG PRICES, AND TREATMENT QUALITY (2007) (2)
An Overview of the Stratified Economics of Stratified Medicine (2015) (2)
PMH30: DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY (2001) (2)
Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets (2019) (2)
Comment on "Can A Disease-Based Price Index Improve the Estimation of the Medical CPI?" (2009) (2)
A theoretical and empirical investigation of the Box-Cox model and a nonlinear least squares alternative (1990) (2)
What Price Shared Governance (2009) (1)
Pepcid AC: Racing to the OTC Market (TN) (2000) (1)
Introduction to "Measuring and Modeling Health Care Costs" (2017) (1)
Pharmaceutical innovation: the authors reply. (2015) (1)
P-12-34: Economic impact of improved work performance after treatment of chronic depression (1996) (1)
PMH23 THE COST CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION (2002) (1)
Energy Intensity and Productivity in U.S. and Japan Manufacturing Industries (1986) (1)
Early Retirement and DI/SSI Applications (2009) (1)
On the economic impacts of medical treatments: work productivity and functioning. (2000) (1)
Where the Money Comes From (2009) (1)
Econometrics and data of the 9 sector Dynamic General Equilibrium Model. Volume III. Final report (1981) (1)
The Blessing and Curse of Shared Governance (2009) (1)
MD2 MEASURING HEALTH IMPACTS ON WORK PERFORMANCE: COMPARING SUBJECTIVE AND OBJECTIVE REPORTS (2002) (1)
The geography of prescription pharmaceuticals supplied to the USA: levels, trends, and implications (2021) (1)
How Quickly Do Physicians Adopt New Drugs (2013) (1)
System average rates of U.S. investor-owned electric utilities : a statistical benchmark study (1995) (1)
Modelling the Aggregate Demand for Electricity: Simplicity vs. Virtuosity (2015) (1)
The Role of Governing Boards in the New Era (2009) (0)
4. Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues: An Overview of Measurement Issues (2019) (0)
Economic Analysis for Business Decisions (PDF) (2004) (0)
HowQuicklyDoPhysicians AdoptNewDrugs?TheCaseof Second-GenerationAntipsychotics (2013) (0)
Prescription drug prices for the elderly Recent research suggests that there is little difference in the rates of drug price inflation facing older and younger Americans , when age-related patterns of consumption are taken into account (1998) (0)
Front matter, prefatory note (2013) (0)
Wood. Responsibility for Opinions Expressed Herein Rests Solely with the Author (2008) (0)
The Early Years (1952) (0)
The Shape of Things to Come (2009) (0)
Productivity. (Program Report) (2002) (0)
The Faculty Are the University (2009) (0)
Construction Prices: Retrospect and Prospect (1991) (0)
Aggregate Advertising Expenditure in the U.S. Economy: Measurement and Growth Issues in the Digital Era (2021) (0)
Phase Major Depression (2001) (0)
Market Forces in Higher Education (2009) (0)
Drug Shortages in the US: A Tale of Two Prices (2015) (0)
PMH18 HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION (2001) (0)
Reforming the Academic Culture (2009) (0)
Economics of Patents (2014) (0)
Industrial Organization Contemporary Theory And Empirical Applications Solutions (2017) (0)
Call for Papers 3rd ZEW Conference on the Economics of Information and Communication Technologies (2003) (0)
Health Affairs Sustaining Innovations Decline In Economic Returns From New Drugs Raises Questions About (2015) (0)
in Child Injury Mortality in the United States (2001) (0)
Front matter, table of contents, preface and acknowledgement (2007) (0)
Dynamic econometric modeling: Editors' introduction (1988) (0)
Recent research suggests that there is little difference in the rates of drug price inflation facing older and younger Americans, when age-related patterns of consumption are taken into account (1998) (0)
This PDF is a selection from a published volume from the National Bureau of Economic Research Volume Title: Health at Older Ages: The Causes and Consequences of Declining Disability among the Elderly (2011) (0)
List of Contributors, Indices (1991) (0)
Measuring the Productivity of Diabetes Treatment, 1997-2005 (2007) (0)
Leadership Begins with the Trustees (2009) (0)
Trends in the Costs of Outsourced R&D: Evidence from Clinical Trials (2016) (0)
Uncertain prognosis for high-quality diagnostics: (2013) (0)
A Proposal for Deregulation of Public Universities (2009) (0)
The Cargo Cult College (2009) (0)
Why Public Universities Cannot Restrain Costs (2009) (0)
Review of the Energy Productivity Center's least-cost energy-strategy study. Interim report (1983) (0)
British Columbia's Energy Outlook 1976-1991 (1978) (0)
Some Historical Reflections (1991) (0)
ChangesinPhysicianAntipsychotic PrescribingPreferences,2002-2007 (2014) (0)
Correcting Hatch-Waxman: An Author Responds (2008) (0)
Perspectiv e Unique Issues Raised By Drug Benefit Design Why drug policies to contain costs, provide high-quality care, and generate incentives for innovation are so difficult to achieve. (2004) (0)
Aggregate Advertising Expenditure in the U.S. Economy: What&Apos;S Up? Is it Real? (2020) (0)
Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace (2022) (0)
Computers and Economic Growth: Firm-leyel Evidence Computers and Economic Growth: Firm-level Evidence (0)
PMH38: RESPONSE TO NEFAZODONE, CBASP, AND COMBINED THERAPY: IMPLICATIONS FOR CHRONIC DEPRESSION SEVERITY, FUNCTIONAL STATUS AND ECONOMIC OUTCOMES (2000) (0)
Recruiting Presidential Leadership (2009) (0)
Investigating investment in biopharmaceutical R & D Citation (2016) (0)
Can Demand Theory Account for Anomalies in Estimates (2006) (0)
Holding Companies: Size-Related Cost Economies (2005) (0)
Entry, Exit, and Reentry in Mature U.S. Generic Product Markets, 2004-2016 (2018) (0)
Front matter, "Medical Care Output and Productivity" (2001) (0)
Modeling and Measuring Natural Resource Substitution@@@Explorations in Natural Resource Economics (1983) (0)
An Overview of Henry Grabowski’s Scholarly Contributions (2011) (0)
Front matter, prefatory note, table of contents (1991) (0)
Dynamic econometric modeling: Envelope consistent functional separability (1988) (0)
Globalization of sponsored clinical trials: reply (2008) (0)
Making valid inferences from claims data: A comparison of SSRI treatment costs (1999) (0)
Aggregate Advertising Expenditure in the U.S. Economy: What's Up? Is It Real? (2020) (0)
The Contributions of Robert S. Pindyck (2023) (0)
Book Review Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat By Fran Hawthorne. 338 pp. Hoboken, N.J., John Wiley & Sons, 2005. $27.95. 0-471-61091-7 (2005) (0)
Forward into the Past: Productivity Retrogression in the Electric Generating Industry (0)
Being direct. (2005) (0)
Editorial Collaborators (2001) (0)
The University Prime Directive (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ernst R. Berndt?

Ernst R. Berndt is affiliated with the following schools:

Massachusetts Institute of Technology